このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases

2026年5月12日 更新者:Jae Yong Jeon, MD

This study aims to develop and validate an artificial intelligence (AI)-based predictive model to estimate the risk of incident onset of five major diseases or conditions: cardiovascular disease, type 2 diabetes mellitus, breast cancer, low back pain, and osteoarthritis, in adults aged 30 to 60 years.

For each participant, an index date will be defined as the date of a prior health screening or another protocol-defined baseline clinical date. Incident disease status for each target disease or condition will be ascertained by retrospective review of electronic medical records for up to 10 years after the index date.

The study integrates retrospective clinical, health screening, laboratory, imaging, and electronic medical record data with prospectively collected biospecimen, proteomic, genomic, questionnaire, lifestyle, and digital health data. Prospective study procedures will be completed over approximately 1 week, with up to 2 additional weeks if needed.

By combining multimodal data, this study seeks to improve disease risk prediction and to identify clinical and biological factors associated with disease onset, ultimately supporting personalized risk stratification and preventive healthcare strategies.

調査の概要

詳細な説明

This observational study aims to develop and validate an artificial intelligence (AI)-based predictive model for assessing the risk of incident onset of five major diseases or conditions: cardiovascular disease, type 2 diabetes mellitus, breast cancer, low back pain, and osteoarthritis, in adults aged 30 to 60 years.

The study uses a hybrid retrospective and prospective data collection design. Retrospective clinical, health screening, laboratory, imaging, and electronic medical record data will be combined with prospectively collected biospecimen, proteomic, genomic, questionnaire, lifestyle, and digital health data.

For disease-onset analyses, an index date will be defined for each participant as the date of a prior health screening or another protocol-defined baseline clinical date. For each target disease or condition, participants without that target disease or condition at the index date will be classified as incident cases if a new diagnosis is identified in electronic medical records up to 10 years after the index date. Participants without a diagnosis of that target disease or condition through the available observation period will be classified as persistent controls. Disease occurrence will be ascertained through retrospective electronic medical record review rather than through new prospective long-term follow-up.

A total of approximately 1,000 participants will be enrolled. The disease group will include approximately 880 adults aged 30 to 60 years with a confirmed diagnosis of one or more of the five target diseases or conditions. The healthy control group will include approximately 120 adults aged 30 to 60 years without a prior diagnosis of any of the five target diseases or conditions.

Retrospective data collection will include medical records, health screening results, laboratory results, and imaging-related data. Prospective data collection will include blood samples for proteomic and genomic analyses, questionnaires, lifestyle and behavioral data, and digital health assessments. App-based questionnaires and digital assessments will be performed at home over approximately 7 days. If app-based sleep assessment or other digital assessments are not completed within this period, up to 2 additional weeks may be provided.

These multimodal data will be integrated to create a high-dimensional phenomic and omics dataset for AI model development. Machine learning and deep learning approaches will be applied to predict disease risk for each target disease or condition. Model performance will be evaluated using discrimination, diagnostic performance, and calibration metrics. Reclassification metrics will be evaluated only if a prespecified comparator risk score is available for the relevant target disease or condition.

The study aims to improve prediction of disease onset and to enhance understanding of biological and clinical factors associated with disease risk. The resulting model is expected to support personalized risk stratification and preventive healthcare strategies.

研究の種類

観察的

入学 (推定)

1000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Seoul Special City
      • Seoul、Seoul Special City、韓国、05505
        • 募集
        • Seoul ASAN Medical Center
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

This study will involve two distinct groups of participants: a disease group and a healthy control group.

  1. Disease Group:

    The disease group will consist of adults aged 30 to 60 years who have been diagnosed with at least one of the following conditions:

    Type 2 diabetes mellitus Breast cancer Cardiovascular disease Osteoarthritis Low back pain These participants will undergo questionnaires, digital assessments, physical examinations, and blood tests as part of the study.

  2. Healthy Control Group:

The healthy control group will consist of adults aged 30 to 60 years with no prior diagnosis of any of the conditions listed above (type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain).

This group will also undergo similar assessments including questionnaires, physical examinations, and blood tests, but they will not have the aforementioned conditions.

説明

Inclusion Criteria:

  1. Adults aged 30 to 60 years.
  2. Disease group: Participants with a confirmed diagnosis of at least one of the following conditions: type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain.
  3. Healthy control group: Participants with no prior diagnosis of type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain.
  4. No history or current diagnosis of major medical conditions that may affect study outcomes, including but not limited to chronic kidney disease or liver cirrhosis.
  5. Ability to understand the study procedures and provision of written informed consent prior to participation.

Exclusion Criteria:

  1. Participants with incomplete or insufficient clinical or health screening data.
  2. Participants considered inappropriate for study participation by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Disease Group

Adults aged 30 to 60 years with one or more of the five major diseases.

Five major diseases are Cardiovascular Diseases, Diabetes Mellitus, Type 2, Breast Neoplasms, Low Back Pain and Osteoarthritis.

Healthy Control Group
Adults aged 30 to 60 years without five major diseases.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Incident Target Disease or Condition Identified Up to 10 Years After the Index Date
時間枠:Up to 10 years after the index date
Incident target disease or condition will be assessed for five prespecified target diseases or conditions: cardiovascular disease, type 2 diabetes mellitus, breast cancer, low back pain, and osteoarthritis. For each target disease or condition, incident occurrence will be defined as a new diagnosis recorded in electronic medical records after the index date among participants without that target disease or condition at the index date. Results will be summarized separately for each target disease or condition as the number and percentage of participants with incident disease or condition.
Up to 10 years after the index date

二次結果の測定

結果測定
メジャーの説明
時間枠
Discriminative performance of the artificial intelligence model in distinguishing between disease and control groups using baseline data from health screenings and clinical records (AUROC, PR-AUC)
時間枠:Through study completion, approximately 9 months
Discriminative performance will be assessed using the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (PR-AUC). These metrics will evaluate the ability of the artificial intelligence model to distinguish participants with incident target disease or condition from persistent controls. Incident disease status will be ascertained by retrospective electronic medical record review up to 10 years after the index date.
Through study completion, approximately 9 months
Diagnostic Performance of the Artificial Intelligence Model for Predicting Incident Target Diseases or Conditions
時間枠:Through study completion, approximately 9 months
Diagnostic performance will be assessed using sensitivity, specificity, positive predictive value, and negative predictive value at a prespecified risk threshold. These metrics will evaluate the ability of the artificial intelligence model to classify participants with incident target disease or condition and persistent controls. Incident disease status will be ascertained by retrospective electronic medical record review up to 10 years after the index date.
Through study completion, approximately 9 months
Brier Score of the Artificial Intelligence Model for Predicting Incident Target Diseases or Conditions
時間枠:Through study completion, approximately 9 months
The Brier score will be calculated as the mean squared difference between predicted risk and observed incident disease status for the five target diseases or conditions. Incident disease status will be ascertained by retrospective electronic medical record review up to 10 years after the index date. Lower values indicate better prediction accuracy.
Through study completion, approximately 9 months
Calibration Slope of the Artificial Intelligence Model for Predicting Incident Target Diseases or Conditions
時間枠:Through study completion, approximately 9 months
Calibration slope will be estimated by comparing predicted risk with observed incident disease status for the five target diseases or conditions. Incident disease status will be ascertained by retrospective electronic medical record review up to 10 years after the index date. A value close to 1 indicates better calibration.
Through study completion, approximately 9 months
Calibration Intercept of the Artificial Intelligence Model for Predicting Incident Target Diseases or Conditions
時間枠:Through study completion, approximately 9 months
Calibration intercept will be estimated by comparing predicted risk with observed incident disease status for the five target diseases or conditions. Incident disease status will be ascertained by retrospective electronic medical record review up to 10 years after the index date. A value close to 0 indicates better calibration-in-the-large.
Through study completion, approximately 9 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月2日

一次修了 (推定)

2026年10月31日

研究の完了 (推定)

2026年12月31日

試験登録日

最初に提出

2026年4月18日

QC基準を満たした最初の提出物

2026年5月12日

最初の投稿 (実際)

2026年5月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月19日

QC基準を満たした最後の更新が送信されました

2026年5月12日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する